Masshightech.com -- Genzyme Corp. has announced that the U.S. Food and Drug Administration will issue a new decision on its drug for Pompe disease in June. The FDA first rejected the drug in March and then again in November. The second rejection was related to problems with the Allston-based manufacturing plant that produced it. The drug is currently approved in 40 other countries, where it is called Myozyme.
